Hospital
Innovis Health, LLC
Innovis Health, LLC was paid $25.47M by Medicaid between Jan 2018 and Dec 2024, across 208 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoINNOVIS HEALTH, LLC
FARGO, ND 58103
FARGO, ND 58103
33aNPI1215125463assigned 10/11/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$25.47M
24GClaims381,966
24DCodes billed208
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Dakota
Rank by total paid#2 of 8
Median peer was paid$750K
This provider vs. median34×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HURLEY, ALAN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 66,829 | $2.32M | |
| 2019 | 46,436 | $3.36M | |
| 2020 | 38,858 | $2.70M | |
| 2021 | 62,165 | $4.10M | |
| 2022 | 63,229 | $4.75M | |
| 2023 | 59,722 | $4.69M | |
| 2024incomplete | 44,727 | $3.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 47,672 | 37,695 | $7.24M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 53,421 | 41,794 | $6.05M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 22% | 89,552 | 78,402 | $5.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 14,835 | 12,107 | $2.83M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.7% | 12,367 | 9,887 | $941K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 5,798 | 5,191 | $329K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 5,638 | 5,105 | $273K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,159 | 1,058 | $203K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 387 | 363 | $198K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,395 | 6,692 | $138K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 846 | 667 | $121K |
| 36591 | <1% | 18,845 | 17,385 | $94K |
196 more codes
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 1,250 | $89K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 188 | $88K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 527 | $67K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,085 | $66K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 348 | $62K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,392 | $60K |
| 80053 | Comprehensive metabolic panel | <1% | 10,967 | $51K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,976 | $49K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,426 | $45K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,622 | $45K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 56 | $41K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 323 | $34K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,181 | $29K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 459 | $29K |
| 93296 | <1% | 1,163 | $26K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,194 | $26K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 92 | $25K |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 1,388 | $25K |
| 64615 | <1% | 92 | $21K | |
| 87631 | <1% | 228 | $20K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 26 | $20K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 855 | $18K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 747 | $17K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 81 | $17K |
| 0002A | <1% | 631 | $17K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 39 | $16K |
| 0001A | <1% | 669 | $15K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 201 | $15K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 75 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 739 | $14K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 163 | $12K |
| 71045 | Radiologic examination, chest; single view | <1% | 708 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 579 | $10K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $10K |
| 82728 | <1% | 848 | $9K | |
| 84425 | <1% | 577 | $8K | |
| 82607 | <1% | 844 | $8K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 215 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,036 | $7K |
| 93299 | <1% | 236 | $7K | |
| 80061 | Lipid panel | <1% | 859 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 215 | $7K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 93 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,287 | $7K |
| 82746 | <1% | 709 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,810 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,582 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 123 | $5K |
| 82525 | <1% | 560 | $5K | |
| J3490 | Unclassified drugs | <1% | 3,672 | $5K |
| 84590 | <1% | 566 | $4K | |
| 73630 | <1% | 187 | $4K | |
| 84630 | <1% | 580 | $4K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 113 | $4K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 49 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 119 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 282 | $4K |
| 95886 | <1% | 27 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,602 | $3K |
| 93325 | <1% | 52 | $3K | |
| T1016 | Case management, each 15 minutes | <1% | 67 | $3K |
| 93298 | <1% | 111 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 35 | $3K |
| 81513 | <1% | 51 | $3K | |
| 90686 | <1% | 310 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,380 | $3K |
| 92134 | <1% | 605 | $3K | |
| 93320 | <1% | 39 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,274 | $3K |
| 0031A | <1% | 95 | $2K | |
| 94010 | <1% | 95 | $2K | |
| 0240U | <1% | 12 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,120 | $2K |
| 0072A | <1% | 85 | $2K | |
| 98940 | <1% | 125 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 110 | $2K |
| 0124A | <1% | 59 | $2K | |
| 20610 | <1% | 30 | $2K | |
| 86140 | <1% | 549 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 88 | $1K |
| 0004A | <1% | 73 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 17 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 16 | $1K |
| 86780 | <1% | 88 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,818 | $1K |
| 85027 | <1% | 1,137 | $1K | |
| 83735 | <1% | 1,253 | $1K | |
| 94729 | <1% | 170 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,811 | $1K |
| 0071A | <1% | 33 | $987.40 | |
| 84484 | <1% | 509 | $968.88 | |
| 96367 | <1% | 16 | $952.90 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 51 | $880.10 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 511 | $778.65 |
| 81001 | <1% | 1,845 | $730.65 | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 87 | $717.19 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 115 | $664.72 |
| 73610 | <1% | 50 | $664.24 | |
| 87481 | <1% | 51 | $658.61 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 43 | $648.16 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 32 | $630.00 |
| 0012A | <1% | 23 | $599.17 | |
| 0011A | <1% | 22 | $530.08 | |
| 84703 | <1% | 861 | $479.47 | |
| 73120 | <1% | 15 | $475.35 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 656 | $474.90 |
| 11721 | <1% | 56 | $466.62 | |
| 83690 | <1% | 577 | $466.55 | |
| 90480 | <1% | 26 | $451.00 | |
| 86803 | <1% | 105 | $446.51 | |
| 92567 | <1% | 26 | $443.58 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 389 | $438.65 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 58 | $426.55 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,420 | $426.18 |
| Q3014 | Telehealth originating site facility fee | <1% | 53 | $425.14 |
| 84466 | <1% | 104 | $380.85 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 141 | $355.69 |
| 84439 | <1% | 136 | $316.73 | |
| 84481 | <1% | 25 | $309.51 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 315 | $300.13 |
| 73030 | <1% | 33 | $296.10 | |
| 87070 | <1% | 46 | $291.48 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 21 | $285.80 |
| 73562 | <1% | 15 | $265.60 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 26 | $264.88 |
| 0064A | <1% | 19 | $251.88 | |
| 87340 | <1% | 100 | $248.57 | |
| 83540 | <1% | 135 | $220.48 | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 15 | $214.49 |
| 84255 | <1% | 15 | $205.19 | |
| 90656 | <1% | 13 | $188.43 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 31 | $149.77 |
| 87205 | <1% | 45 | $145.40 | |
| 85652 | <1% | 84 | $142.64 | |
| 91320 | <1% | 14 | $124.87 | |
| 87480 | <1% | 222 | $123.16 | |
| 89190 | <1% | 12 | $120.81 | |
| 86705 | <1% | 15 | $117.38 | |
| 90691 | <1% | 12 | $109.37 | |
| 73100 | <1% | 15 | $103.25 | |
| 81003 | <1% | 674 | $89.69 | |
| 86431 | <1% | 28 | $81.35 | |
| G0008 | Administration of influenza virus vaccine | <1% | 27 | $80.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 32 | $77.60 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 456 | $69.75 |
| 86704 | <1% | 14 | $54.79 | |
| 87081 | <1% | 520 | $47.70 | |
| 86706 | <1% | 14 | $46.75 | |
| 83605 | <1% | 51 | $34.71 | |
| 82248 | <1% | 55 | $16.72 | |
| 87660 | <1% | 222 | $6.10 | |
| 87510 | <1% | 222 | $6.10 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 27 | $4.32 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| 91300 | 0% | 246 | $0.00 | |
| 87186 | 0% | 165 | $0.00 | |
| 87653 | 0% | 44 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 188 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 174 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 454 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 207 | $0.00 |
| 85610 | 0% | 314 | $0.00 | |
| 84702 | 0% | 149 | $0.00 | |
| 74018 | 0% | 14 | $0.00 | |
| 87420 | 0% | 51 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 18 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 42 | $0.00 |
| 80347 | 0% | 30 | $0.00 | |
| 86900 | 0% | 14 | $0.00 | |
| 84156 | 0% | 12 | $0.00 | |
| 82570 | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 17 | $0.00 |
| 82962 | 0% | 307 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 201 | $0.00 |
| 82550 | 0% | 69 | $0.00 | |
| 87077 | 0% | 184 | $0.00 | |
| 88142 | 0% | 144 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 1,235 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 97 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 124 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 165 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 17 | $0.00 |
| 96376 | 0% | 74 | $0.00 | |
| 86762 | 0% | 29 | $0.00 | |
| 86901 | 0% | 14 | $0.00 | |
| 91303 | 0% | 13 | $0.00 | |
| 82043 | 0% | 49 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 63 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 21 | $0.00 |
| 85379 | 0% | 32 | $0.00 | |
| 82950 | 0% | 32 | $0.00 | |
| 83880 | 0% | 25 | $0.00 | |
| 82553 | 0% | 14 | $0.00 | |
| 73502 | 0% | 15 | $0.00 | |
| 85730 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHURLEY, ALAN (COO)
Parent organizationESSENTIA HEALTH
| Provider | Location | Paid |
|---|---|---|
| ST Mary's Regional Health Center | Park Rapids, MN | $21.51M |
| ST. Marys Regional Health Center | Detroit Lakes, MN | $18.64M |
| ST Mary's Regional Health Center | Detroit Lakes, MN | $6.79M |
| Innovis Health LLC | Fargo, ND | $5.11M |
| Innovis Health LLC | Fargo, ND | $4.44M |
| ST Marys Regional Health Center | Park Rapids, MN | $4.26M |
| Bridges Medical Center | Ada, MN | $2.02M |
| ST Mary's Regional Health Center | Walker, MN | $1.86M |
| Graceville Health Center | Graceville, MN | $1.04M |
| Innovis Health, LLC. | Jamestown, ND | $990K |
| Innovis Health LLC | Moorhead, MN | $899K |
| Innovis Health LLC | Fargo, ND | $862K |
| ST Mary's Regional Health Center | Menahga, MN | $849K |
| ST Marys Regional Health Center | Detroit Lakes, MN | $806K |
| ST. Mary's Regional Health Center | Mahnomen, MN | $804K |
| Innovis Health LLC | Moorhead, MN | $795K |
| Innovis Health, LLC | Valley City, ND | $753K |
| Innovis Health, LLC | Bismarck, ND | $538K |
| Innovis Health, LLC. | Wahpeton, ND | $465K |
| ST. Mary's Regional Health Center | Pelican Rapids, MN | $459K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.